Form 4: Travere Therapeutics Executive Sells Shares Under 10b5-1 Plan

Elizabeth E. Reed, SVP, GC & Corporate Secretary of Travere Therapeutics, sold 2,437 shares of common stock at $19.46 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Elizabeth E. Reed, a senior executive at Travere Therapeutics, sold 2,437 shares of the company's common stock.
• The sale occurred on January 22, 2025, at a price of $19.46 per share.
• This transaction was executed under a pre-arranged trading plan (Rule 10b5-1) adopted on March 15, 2024.
• The sale included shares to cover tax obligations from the vesting of restricted stock units.
• Following the transaction, Ms. Reed directly owns 76,933 shares of Travere Therapeutics stock.
• This total includes 737 shares acquired through the company's Employee Stock Purchase Plan on November 29, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The sale is part of a pre-arranged plan, which is a normal practice. The executive still holds a significant number of shares, indicating continued alignment with the company.

Positives

• The sale was conducted under a pre-arranged 10b5-1 trading plan, which is a common practice for executives to avoid accusations of insider trading.
• The executive still holds a significant number of shares (76,933) after the sale, indicating continued alignment with the company's performance.

Negatives

• The sale of shares by a high-ranking executive could be perceived negatively by some investors, although it is a common practice under 10b5-1 plans.

Risks

• Executive stock sales, even under pre-arranged plans, can sometimes create short-term downward pressure on the stock price.
• There is a risk that investors might interpret the sale as a lack of confidence in the company's future prospects, although this is not necessarily the case.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies, often managed through pre-arranged 10b5-1 plans to avoid insider trading concerns. This transaction is typical for executives managing their personal finances and stock holdings.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a standard practice among executives at publicly traded companies, including those in the biotechnology and pharmaceutical sectors like Travere Therapeutics.
• Similar transactions are regularly reported by executives at companies such as BioMarin Pharmaceutical, Vertex Pharmaceuticals, and Regeneron Pharmaceuticals, all of which are comparable in size and industry to Travere Therapeutics.
• The volume of shares sold (2,437) is relatively small compared to the total shares owned (76,933), which is a common pattern in executive stock sales.

Stakeholder Impact

• The stock sale could have a minor impact on shareholders, potentially causing a slight dip in the stock price in the short term.
• The sale does not appear to have any direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Travere Therapeutics, stock sale, insider trading, Form 4, 10b5-1 plan, executive, share sale, equity